Lilly Antibody Therapies Given Emergency Authorization
The U.S. Food and Drug Administration has granted an Emergency Use Authorization for two COVID-19 antibody therapies from Indianapolis-based Eli Lilly and Co. (NYSE: LLY). The company says the combination of bamlanivimab and etesevimab can be used for the treatment of mild-to-moderate COVID-19 in [点击 More>>>]